bmb-101
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 6, 2022 (NCT05397041)
Timeline
Indications
Mechanism of action
HTR2C agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266324 | Phase 2 | Jan 31, 2026 | Bright Minds Biosciences |
| NCT06401538 | Phase 2 | Sep 15, 2024 | Bright Minds Biosciences, Monash University |
| NCT05397041 | Phase 1 | Jun 6, 2022 | Bright Minds Biosciences, CMAX Clinical Research |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bright Minds Biosciences | For profit | 3 | 3 | 2 | 2022 |
| CMAX Clinical Research | For profit | 1 | 0 | 1 | 2022 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1